

P&T Committee Review Meeting Minutes

Subject:	Louisiana Department of Health Medicaid Pharmaceutical and Therapeutic Committee Review
Location:	628 NORTH 4TH STREET, ROOM 118 BATON ROUGE, LOUISIANA 70802
Date:	November 5, 2025
Members Present:	<ul style="list-style-type: none"> ▪ Jill Comeau ▪ Dr. Vanessa De La Cruz ▪ Tammy Hart ▪ Charles Coleman ▪ Pamela G. Reed ▪ Dr. Mary Raven ▪ Sheri Huval ▪ Dr. Kathleen Willis
LDH Staff Present:	<ul style="list-style-type: none"> ▪ Kimberly Boudreaux ▪ Katrina Johnson ▪ Sue Fontenot, RPh ▪ Rachel Broussard, RPh
Contractors Present:	<ul style="list-style-type: none"> ▪ Hind Douiki, PharmD, Prime Therapeutics State Government Solutions ▪ Renesha Yarbrough, PharmD, Prime Therapeutic State Government Solutions
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Ms. Comeau announced that there is a quorum and called the meeting to order at 9:00am. She asked the committee members introduce themselves.

Parliamentary Business

- A. **Introduction of Members/Roll Call.** Jill Comeau asked P&T Committee members and LDH staff to introduce themselves.
- B. **Approval of October 30, 2024 Meeting and May 5, 2025 Meeting Minutes.** Jill Comeau stated since there is a quorum we have two different meeting minutes to vote on for approval. Mr. Coleman moved to

accept those minutes. Dr. De La Cruz second. All in favor to approve minutes.

Ethics

Ms. Boudreaux presented a refresher on governmental ethics for the P&T committee members. She indicated Louisiana Code of Governmental Ethics is in Title 42 of our Louisiana Revised Statutes. The basic idea is to keep everything honest, fair, and transparent in government actions, so we don't want to use public office for private gain. &T Committee members are deemed state employees for ethics purposes and cannot accept gifts from pharmaceutical companies except samples and low-value promotional items with logos. Members cannot accept meals over \$50 and must consume them in the giver's presence. Exceptions exist for conferences with large gatherings. Members cannot be reimbursed by prohibited sources and cannot solicit grants. LDH opines members don't need to file Financial Disclosure Statements, though members should seek Board of Ethics confirmation. Pharmaceutical representatives lobbying committee members must register as lobbyists.

Reports

Ms. Fontenot informed the P&T Committee members that effective October 1, 2025, Medicaid transitioned away from the SinglePBM and now each MCO utilizes their own PBM to process pharmacy claims and prior authorizations. She advised the unified preferred drug list for which this P&T Committee provides recommendations remains in place. As of quarter two of 2025 prior to the transition from the SinglePBM, the overall MCO PDL compliance rate was 96.5%. The MCOs are contractually required to maintain a compliance rate of at least 92%. The performance continues to exceed expectations. The transition to individual PBMs introduces operational changes; however, early indicators suggest continued commitment to high levels of compliance and consistent application of the preferred drug list across all participating MCOs.

Public Testimony

Ms. Douiki asked that any member of the public who wished to provide testimony to wait until their therapeutic class is reviewed and then raise their hand once the Chair asks if there is any public testimony. Once the testimony is started, a timer will be placed on the screen. She kindly asked that any speaker who has signed up to provide testimony and their drug is preferred, to give their time back.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Ms. Douiki provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She presented information about clinical and financial components of the recommendation process. She also summarized the supplemental rebate process. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates...etc. The committee members should also have cost sheets which include relative values, rather than actual numbers, in order to comply with the privacy laws regarding rebates.

B. Therapeutic Class Reviews of Fall Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Lynda Finch	Biogen	Zurzuvae
Jay Mehta	Axsome	Auvelity
Mr. Stefan Luft	Luye Pharma	Erzofri
Tim Birner	Alkermes	Lybalvi
Tamara Reado	Johnson and Johnson	Caplyta
Alex Brewer III	UCB	Bimzelx
Julie Seubolt	Amgen	Otezla
Dr. Tracy Wilson	ARS Pharma	Neffy
Randy Ferreter	AstraZeneca	Airsupra
Jeffery Olearzyk	Amgen	Tezspire
Carla McSpadden	Galderma	Nemluvio
Joe Cirrincione	Incyte	Opzelura
Valerie Ng	LEO Pharma	Adbry
Troy Lin	Organon	Vtama
Elizabeth Lubelczyk**	Lilly	Ebglyss
Michael Mccallum	Rare Disease Therapeutics	Xromi
Jessica Jay	Vertex Pharma	Journavax & Casgevy
Lynda Finch	Biogen	Spinraza
Herbert Peeples**	UCB	Nayzilam
**NOTE: Names of speakers who were present and yielded their time back were not captured or contain the double asterisk.		

Alzheimer's Agents

Recommendations for the PDL are:

- DONEPEZIL ODT (ORAL)
- DONEPEZIL TABLET (ORAL)
- MEMANTINE TABLET (AG) (ORAL)
- MEMANTINE TABLET (ORAL)
- RIVASTIGMINE (AG) (TRANSDERM.)

- RIVASTIGMINE (TRANSDERM.)
- RIVASTIGMINE CAPSULES (ORAL)

There were no further discussions made by the committee about this class.

Anthelmintics

Recommendations for the PDL are:

- ALBENDAZOLE (ORAL)
- EMVERM (ORAL)
- IVERMECTIN (ORAL)
- PRAZIQUANTEL (ORAL)

There were no further discussions made by the committee about this class.

Anti-Allergens, Oral

Recommendations for the PDL are:

- None. All drugs in this class non-preferred.

There were no further discussions made by the committee about this class.

Anticonvulsants

Recommendations for the PDL are:

- BRIVIACT SOLUTION (ORAL) BRIVIACT TABLET (ORAL)
- BRIVIACT TABLET (ORAL)
- CARBAMAZEPINE 100MG CHEWABLE TABLET (ORAL)
- CARBAMAZEPINE ER (CARBATROL) (ORAL)
- CARBAMAZEPINE TABLET (ORAL)
- CARBAMAZEPINE XR (ORAL)
- CLOBAZAM SUSPENSION (ORAL)
- CLOBAZAM TABLET (ORAL)
- CLONAZEPAM (ORAL)
- CLONAZEPAM ODT (ORAL)
- DIAZEPAM (AG) (RECTAL)
- DIAZEPAM DEVICE (AG) (RECTAL)
- DILANTIN 30 MG CAPSULE (ORAL)
- DIVALPROEX ER (ORAL)
- DIVALPROEX SPRINKLE (ORAL)
- DIVALPROEX TABLET (ORAL)
- EPIDIOLEX (ORAL)
- ETHOSUXIMIDE CAPSULE (ORAL)
- ETHOSUXIMIDE SYRUP (ORAL)

- LACOSAMIDE SOLUTION (ORAL)
- LACOSAMIDE TABLET (ORAL)
- LAMOTRIGINE DISPERSIBLE TABLET (ORAL)
- LAMOTRIGINE TABLET (ORAL)
- LAMOTRIGINE XR (ORAL)
- LEVETIRACETAM ER (ORAL)
- LEVETIRACETAM SOLUTION (ORAL)
- LEVETIRACETAM TABLETS (ORAL)
- NAYZILAM (NASAL)
- OXCARBAZEPINE SUSPENSION (ORAL)
- OXCARBAZEPINE TABLETS (ORAL)
- PHENOBARBITAL ELIXIR (ORAL)
- PHENOBARBITAL TABLET (ORAL)
- PHENYTOIN CAPSULE (ORAL)
- PHENYTOIN CHEWABLE TABLET (ORAL)
- PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)
- PHENYTOIN SUSPENSION (AG) (ORAL)
- PHENYTOIN SUSPENSION (ORAL)
- PRIMIDONE (ORAL)
- RUFINAMIDE SUSPENSION (ORAL)
- RUFINAMIDE TABLET (ORAL)
- SEZABY (INTRAVEN)
- TOPIRAMATE SPRINKLE (ORAL)
- TOPIRAMATE TABLETS (ORAL)
- VALPROIC ACID CAPSULE (ORAL)
- VALPROIC ACID SOLUTION (ORAL)
- VALTOCO (NASAL)
- XCOPRI TABLET (ORAL)
- XCOPRI TITRATION PAK (ORAL)
- ZONISAMIDE (ORAL)

There were no further discussions made by the committee about this class.

Antidepressants, Other

Recommendations for the PDL are:

- BUPROPION (ORAL)
- BUPROPION SR (ORAL)
- BUPROPION XL (ORAL)
- DESVENLAFAXINE ER (PRISTIQ) (ORAL)
- MIRTAZAPINE ODT (ORAL)
- MIRTAZAPINE TABLET (ORAL)
- TRAZODONE (ORAL)

- VENLAFAXINE (ORAL)
- VENLAFAXINE ER CAPSULES (ORAL)
- VILAZODONE (AG) (ORAL)
- VILAZODONE (ORAL)

There were no further discussions made by the committee about this class.

Antidepressants, SSRIs

Recommendations for the PDL are:

- CITALOPRAM SOLUTION (ORAL)
- CITALOPRAM TABLET (ORAL)
- ESCITALOPRAM TABLET (ORAL)
- FLUOXETINE CAPSULE (ORAL)
- FLUOXETINE SOLUTION (ORAL)
- FLUVOXAMINE (ORAL)
- PAROXETINE TABLET (ORAL)
- SERTRALINE CONC (ORAL)
- SERTRALINE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Antihistamines, Minimally Sedating

Recommendations for the PDL:

- CETIRIZINE SOLUTION (ORAL)
- CETIRIZINE SOLUTION OTC (ORAL)
- CETIRIZINE TABLETS OTC (ORAL)
- CETIRIZINE-D OTC (ORAL)
- DESLORATADINE (ORAL)
- FEXOFENADINE 60, 180 MG OTC (ORAL)
- LEVOCETIRIZINE TABLETS (ORAL)
- LEVOCETIRIZINE TABLETS OTC (ORAL)
- LORATADINE ODT OTC (ORAL)
- LORATADINE SOLUTION OTC (ORAL)
- LORATADINE TABLETS OTC (ORAL)
- LORATADINE-D OTC (ORAL)

There were no further discussions made by the committee about this class.

Antihypertensives, Sympatholytics

Recommendations for the PDL:

- CLONIDINE (AG) (TRANSDERM)
- CLONIDINE (ORAL)
- CLONIDINE (TRANSDERM)
- GUANFACINE (ORAL)

- METHYLDOPA (AG) (ORAL)
- METHYLDOPA (ORAL)

There were no further discussions made by the committee about this class.

Antihyperuricemics

Recommendations for the PDL are:

- ALLOPURINOL (ORAL) [100mg, 300mg]
- COLCHICINE TABLET (AG) (ORAL)
- COLCHICINE TABLET (ORAL)
- FEBUXOSTAT (ORAL)
- PROBENECID (ORAL)
- PROBENECID / COLCHICINE (ORAL)

There were no further discussions made by the committee about this class.

Antiparkinson's Agents

Recommendations for the PDL are:

- AMANTADINE CAPSULE (ORAL)
- AMANTADINE SYRUP (ORAL)
- BENZTROPINE (ORAL)
- CARBIDOPA / LEVODOPA (ORAL)
- CARBIDOPA / LEVODOPA ER (ORAL)
- PRAMIPEXOLE (ORAL)
- ROPINIROLE (ORAL)
- SELEGILINE TABLET (ORAL)
- TRIHEXYPHENIDYL ELIXIR (ORAL)
- TRIHEXYPHENIDYL TABLET (ORAL)

There were no further discussions made by the committee about this class.

Antipsoriatics, Oral

Recommendations for the PDL are:

- ACITRETIN (ORAL)

There were no further discussions made by the committee about this class.

Antipsoriatics, Topical

Recommendations for the PDL are:

- CALCIPOTRIENE CREAM (TOPICAL)
- CALCIPOTRIENE SOLUTION (TOPICAL)

There were no further discussions made by the committee about this class.

Antipsychotics

Recommendations for the PDL are:

- ABILIFY ASIMTUFII (INTRAMUSC)
- ABILIFY MAINTENA (INTRAMUSC.)
- AMITRIPTYLINE / PERPHENAZINE (ORAL)
- ARIPIPRAZOLE TABLET (ORAL)
- ARISTADA (INTRAMUSC)
- ARISTADA INITIO (INTRAMUSC)
- CHLORPROMAZINE (ORAL)
- CLOZAPINE (ORAL) [Tablet]
- FLUPHENAZINE DECANOATE (INJECTION)
- FLUPHENAZINE TABLET (ORAL)
- HALOPERIDOL (ORAL)
- HALOPERIDOL DECANOATE (INJECTION)
- HALOPERIDOL LACTATE (INJECTION)
- HALOPERIDOL LACTATE CONC (ORAL)
- INVEGA HAFYERA (INTRAMUSC)
- INVEGA SUSTENNA (INTRAMUSC)
- INVEGA TRINZA (INTRAMUSC)
- LOXAPINE (ORAL)
- LURASIDONE (ORAL)
- OLANZAPINE ODT (ORAL)
- OLANZAPINE TABLET (ORAL)
- PALIPERIDONE (ORAL)
- PERPHENAZINE (ORAL)
- PERSERIS (SUBCUTANEOUS)
- PIMOZIDE (ORAL)
- QUETIAPINE ER (ORAL)
- QUETIAPINE TABLETS(ORAL)
- RISPERIDONE (INTRAMUSC)
- RISPERIDONE SOLUTION (ORAL)
- RISPERIDONE TABLET (ORAL)
- THIORIDAZINE (ORAL)
- THIOTHIXENE (ORAL)
- TRIFLUOPERAZINE (ORAL)
- UZEDY (SUBCUTANEOUS)
- VRAYLAR (ORAL)
- ZIPRASIDONE (INTRAMUSC)
- ZIPRASIDONE CAPSULE (AG) (ORAL)
- ZIPRASIDONE CAPSULE (ORAL)

There were no further discussions made by the committee about this class.

Antivirals, General

Recommendations for the PDL are:

- PAXLOVID TAB DS PK (ORAL)
- VALGANCICLOVIR SOLUTION (ORAL)
- VALGANCICLOVIR TABLET (ORAL)

There were no further discussions made by the committee about this class.

Anxiolytics

Recommendations for the PDL are:

- ALPRAZOLAM TABLET (ORAL)
- BUSPIRONE (ORAL)
- LORAZEPAM TABLET (ORAL)

There were no further discussions made by the committee about this class.

Bile Salts

Recommendations for the PDL are:

- URSODIOL 300 MG CAPSULE (ORAL)
- URSODIOL TABLET (ORAL)

There were no further discussions made by the committee about this class.

Botulinum Toxins

Recommendations for the PDL are:

- BOTOX (INTRAMUSC)
- DYSPORT (INTRAMUSC)

There were no further discussions made by the committee about this class.

Bronchodilators, Beta Agonist

Recommendations for the PDL are:

- ALBUTEROL HFA (PROAIR) (AG) (INHALATION)
- ALBUTEROL HFA (PROAIR) (INHALATION)
- ALBUTEROL HFA (PROVENTIL) (AG) (INHALATION)
- ALBUTEROL HFA (PROVENTIL) (INHALATION)
- ALBUTEROL HFA (VENTOLIN) (AG) (INHALATION)
- ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)

- ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)
- SEREVENT (INHALATION)

There were no further discussions made by the committee about this class.

Colony Stimulating Factors

Recommendations for the PDL are:

- FULPHILA (SUBCUTANEOUS)
- FYLNETRA (SUBCUTANEOUS)
- NEUPOGEN DISP SYRIN (INJECTION)
- NEUPOGEN VIAL (INJECTION)

There were no further discussions made by the committee about this class.

COPD Agents

Recommendations for the PDL are:

- ATROVENT HFA (INHALATION)
- COMBIVENT RESPIMAT (INHALATION)
- IPRATROPIUM / ALBUTEROL (INHALATION)
- IPRATROPIUM NEBULIZER (INHALATION)
- ROFLUMILAST (ORAL)
- STIOLTO RESPIMAT (INHALATION)
- TIOTROPIUM (INHALATION)

There were no further discussions made by the committee about this class.

Cytokine and CAM Antagonists

Recommendations for the PDL are:

- ADALIMUMAB-AATY KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-AATY PEN KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADAZ KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADAZ PEN KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADBIM KIT (BI) (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADBIM KIT (BI) (INJECTION) (CF) 50 MG/ML
- ADALIMUMAB-ADBIM PEN KIT (BI) (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADBIM PEN KIT (BI) (INJECTION) (CF) 50 MG/ML
- ENBREL MINI CARTRIDGE (SUBCUTANE.)
- ENBREL PEN (INJECTION)
- ENBREL SYRINGE (INJECTION)
- ENBREL VIAL (SUBCUTANE.)
- HADLIMA KIT (INJECTION) (CF) 100 MG/ML
- HADLIMA KIT (INJECTION) 50 MG/ML

- HADLIMA PEN KIT (INJECTION) (CF) 100 MG/ML
- HADLIMA PEN KIT (INJECTION) 50 MG/ML
- HUMIRA KIT (INJECTION) (CF) 100 MG/ML
- HUMIRA KIT (INJECTION) 50 MG/ML
- HUMIRA PEN KIT (INJECTION) (CF) 100 MG/ML
- HUMIRA PEN KIT (INJECTION) 50 MG/ML
- INFLIXIMAB (INJECTION)
- OTEZLA (ORAL)
- PYZCHIVA SYRINGE (SUBCUTANEOUS)
- PYZCHIVA VIAL (INTRAVENOUS)
- PYZCHIVA VIAL (SUBCUTANE.)
- SELARSDI SYRINGE (SUBCUTANE.)
- STEQEYMA SYRINGE (SUBCUTANE.)
- STEQEYMA VIAL (INTRAVENOUS)
- TALTZ AUTOINJECTOR (SUBCUTANE.)
- TALTZ SYRINGE (SUBCUTANE.)
- XELJANZ (ORAL)

Duchenne Muscular Dystrophy Treatments

Recommendations for the PDL are:

- None. All drugs in this class non-preferred.

There were no further discussions made by the committee about this class.

Emollients

Recommendations for the PDL are:

- AMMONIUM LACTATE CREAM/LOTION (TOPICAL)

There were no further discussions made by the committee about this class.

Enzyme Replacement, Gauchers Disease

Recommendations for the PDL are:

- None. All drugs in this class non-preferred.

There were no further discussions made by the committee about this class.

Epinephrine, Self-Administered

Recommendations for the PDL are:

- AUVI-Q 0.1 MG (INTRAMUSC)
- AUVI-Q 0.15 MG (INTRAMUSC)
- AUVI-Q 0.3 MG (INTRAMUSC)
- EPINEPHRINE 0.15 MG (EPIPEN JR) (AG) (INJECTION)

- EPINEPHRINE 0.15 MG (EPIPEN JR) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (AG) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (INJECTION)

There were no further discussions made by the committee about this class.

Erythropoiesis Stimulating Proteins

Recommendations for the PDL are:

- ARANESP DISP SYRIN (INJECTION)
- ARANESP VIAL (INJECTION)
- EPOGEN (INJECTION)
- RETACRIT (INJECTION)

There were no further discussions made by the committee about this class.

Glucocorticoids, Inhaled

Recommendations for the PDL are:

- ASMANEX (INHALATION)
- ASMANEX HFA (INHALATION)
- BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)
- BUDESONIDE 1 MG RESPULES (INHALATION)
- BUDESONIDE/FORMOTEROL (AG) (INHALATION)
- BUDESONIDE/FORMOTEROL (INHALATION)
- DULERA (INHALATION)
- FLUTICASONE (ARNUITY ELLIPTA) (AG) INHALATION
- FLUTICASONE HFA (AG) (INHALATION)
- FLUTICASONE/SALMETEROL (ADVAIR) (AG) (INHALATION)
- FLUTICASONE/SALMETEROL (ADVAIR) (INHALATION)
- FLUTICASONE/SALMETEROL HFA (AG) (INHALATION)
- QVAR REDHALER (INHALATION)
- TRELEGY ELLIPTA (INHALATION)

There were no further discussions made by the committee about this class.

Glucocorticoids, Oral

Recommendations for the PDL are:

- BUDESONIDE EC (ORAL)
- DEXAMETHASONE TABLET (ORAL)

- HYDROCORTISONE (ORAL)
- METHYLPREDNISOLONE TAB DS PK (ORAL)
- PREDNISOLONE SODIUM PHOSPHATE (ORAL)
- PREDNISOLONE SOLUTION (ORAL)
- PREDNISON TABLET (ORAL)

There were no further discussions made by the committee about this class.

Hemophilia Treatment

Recommendations for the PDL are:

- ALPHANATE (INTRAVEN.)
- BENEFIX KIT (INTRAVEN.)
- COAGADEX (INTRAVEN)
- CORIFACT KIT (INTRAVEN)
- HEMLIBRA (SUBCUTANE.)
- HUMATE-P KIT (INTRAVEN.)
- JIVI (INTRAVEN)
- KOVALTRY (INTRAVEN.)
- NOVOEIGHT (INTRAVEN)
- NOVOSEVEN RT (INTRAVEN)
- NUWIQ (INTRAVEN)
- REBINYN (INTRAVEN)
- WILATE (INTRAVEN)
- XYNTHA KIT (INTRAVEN)
- XYNTHA SOLOFUSE SYRINGE KIT (INTRAVEN.)

There were no further discussions made by the committee about this class.

Histamine II Receptor Blocker

Recommendations for the PDL are:

- FAMOTIDINE SUSPENSION (ORAL)
- FAMOTIDINE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Idiopathic Pulmonary Fibrosis

Recommendations for the PDL are:

- OFEV (ORAL)
- PIRFENIDONE CAPSULE (ESBRIET) (ORAL)

- PIRFENIDONE TABLET (ESBRIET) (ORAL)

There were no further discussions made by the committee about this class.

Immune Globulins

Recommendations for the PDL are:

- GAMMAGARD LIQUID (INJECTION)
- GAMUNEX-C (INJECTION)
- HIZENTRA SYRINGE (SUBCUTANEOUS)
- HIZENTRA VIAL (SUBCUTANEOUS)
- PRIVIGEN (INTRAVEN)

There were no further discussions made by the committee about this class.

Immunomodulators, Asthma

Recommendations for the PDL are:

- FASENRA PEN (SUBCUTANEOUS)
- FASENRA SYRINGE (SUBCUTANEOUS)
- XOLAIR SYRINGE/AUTOINJ (SUB-Q)
- XOLAIR VIAL (SUB-Q)

There were no further discussions made by the committee about this class.

Immunomodulators, Atopic Dermatitis

Recommendations for the PDL are:

- ADBRY AUTOINJECTOR (SUBCUTANEOUS)
- ADBRY SYRINGE (SUBCUTANEOUS)
- DUPIXENT PEN (SUBCUTANEOUS)
- DUPIXENT SYRINGE (SUBCUTANEOUS)
- EBGLYSS PEN (SUBCUTANEOUS)
- EBGLYSS SYRINGE (SUBCUTANEOUS)
- EUCRISA (TOPICAL)
- OPZELURA (TOPICAL)
- PIMECROLIMUS (AG) (TOPICAL)
- PIMECROLIMUS (TOPICAL)
- TACROLIMUS (AG) (TOPICAL)
- TACROLIMUS (TOPICAL)

There were no further discussions made by the committee about this class.

Immunomodulators, Lupus

Recommendations for the PDL are:

- None. All drugs in this class are non-preferred.

There were no further discussions made by the committee about this class.

Immunomodulators, Topical

Recommendations for the PDL are:

- IMIQUIMOD (ALDARA) (TOPICAL)

There were no further discussions made by the committee about this class.

Intranasal Rhinitis Agents

Recommendations for the PDL are:

- AZELASTINE (ASTELIN) (NASAL)
- FLUTICASONE (NASAL)
- IPRATROPIUM (NASAL)

There were no further discussions made by the committee about this class.

Iron, Oral

Recommendations for the PDL are:

- FERROUS GLUCONATE TABLET OTC (ORAL)
- FERROUS SULFATE DROPS OTC (ORAL)
- FERROUS SULFATE SOLUTION OTC (ORAL)
- FERROUS SULFATE TABLET OTC (ORAL)
- IRON POLYSACCHARIDES CAPSULE OTC (ORAL)

There were no further discussions made by the committee about this class.

Leukotriene Modifiers

Recommendations for the PDL are:

- MONTELUKAST CHEWABLE TABLET (ORAL)
- MONTELUKAST TABLET (ORAL)

There were no further discussions made by the committee about this class.

Methotrexate

Recommendations for the PDL are:

- METHOTREXATE PF VIAL (AG) (INJECTION)
- METHOTREXATE PF VIAL (INJECTION)
- METHOTREXATE TABLET (ORAL)
- METHOTREXATE VIAL (INJECTION)

There were no further discussions made by the committee about this class.

Movement Disorders

Recommendations for the PDL are:

- AUSTEDO (ORAL)
- AUSTEDO XR (ORAL)
- AUSTEDO XR TITRATION KIT (ORAL)
- INGREZZA (ORAL)
- INGREZZA INITIATION PACK (ORAL)
- INGREZZA SPRINKLE (ORAL)
- TETRABENAZINE (ORAL)

There were no further discussions made by the committee about this class.

Neuropathic Pain and Select Agents

Recommendations for the PDL are:

- DULOXETINE (CYMBALTA) (ORAL)
- GABAPENTIN CAPSULE (ORAL)
- GABAPENTIN SOLUTION (AG) (ORAL)
- GABAPENTIN SOLUTION (ORAL)
- GABAPENTIN TABLET (ORAL)
- JOURNAVX TABLET (ORAL)
- LIDOCAINE (AG) (TOPICAL)
- LIDOCAINE (TOPICAL)
- PREGABALIN CAPSULE (AG) (ORAL)
- PREGABALIN CAPSULE (ORAL)
- PREGABALIN SOLUTION (AG) (ORAL)
- PREGABALIN SOLUTION (ORAL)
- SAVELLA (ORAL)
- SAVELLA DOSE PACK (ORAL)

There were no further discussions made by the committee about this class.

Non-CF Bronchiectasis Agents

Recommendations for the PDL are:

- None. All drugs in the class non-preferred.

There were no further discussions made by the committee about this class.

NSAIDS

Recommendations for the PDL are:

- CELECOXIB (AG) (ORAL)
- CELECOXIB (ORAL)
- DICLOFENAC GEL (TOPICAL)
- DICLOFENAC SODIUM (ORAL)
- IBUPROFEN SUSPENSION (ORAL)
- IBUPROFEN TABLET (ORAL)
- INDOMETHACIN CAPSULE (ORAL)
- KETOROLAC (ORAL)
- MELOXICAM TABLET (ORAL)
- NABUMETONE (ORAL)
- NAPROXEN SUSPENSION (AG) (ORAL)
- NAPROXEN SUSPENSION (ORAL)
- NAPROXEN TABLET (ORAL)
- SULINDAC (ORAL)

There were no further discussions made by the committee about this class.

Oncology, Oral-Breast

Recommendations for the PDL are:

- ANASTROZOLE (ORAL)
- CAPECITABINE (ORAL)
- CYCLOPHOSPHAMIDE (ORAL)
- EXEMESTANE (ORAL)
- KISQALI (ORAL)
- LETROZOLE (ORAL)
- TAMOXIFEN CITRATE (ORAL)

There were no further discussions made by the committee about this class.

Oncology, Oral-Hematologic

Recommendations for the PDL are:

- DASATINIB (ORAL)
- DASATINIB (ORAL) (AG)
- HYDROXYUREA (ORAL)
- IMATINIB (ORAL)
- IMBRUVICA CAPSULE (ORAL)
- IMBRUVICA TABLET (ORAL)
- JAKAFI (ORAL)
- LENALIDOMIDE (ORAL)
- MATULANE (ORAL)

- MERCAPTOPYRINE (ORAL)
- REVLIMID (ORAL)
- TRETINOIN (ORAL)
- VENCLEXTA (ORAL)
- VENCLEXTA STARTING PACK (ORAL)

There were no further discussions made by the committee about this class.

Oncology, Oral-Lung

Recommendations for the PDL are:

- ALECENSA (ORAL)
- GILOTRIF (ORAL)
- Hycamtin (ORAL)
- TAGRISSO (ORAL)
- XALKORI (ORAL)

There were no further discussions made by the committee about this class.

Oncology, Oral-Other

Recommendations for the PDL are:

- KOSELUGO (ORAL)
- LYNPARZA (ORAL)
- TEMOZOLOMIDE (ORAL)

There were no further discussions made by the committee about this class.

Oncology, Oral-Prostate

Recommendations for the PDL are:

- ABIRATERONE (ORAL)
- BICALUTAMIDE (ORAL)
- XTANDI CAPSULE (ORAL)
- XTANDI TABLET (ORAL)

There were no further discussions made by the committee about this class.

Oncology, Oral-Renal Cell

Recommendations for the PDL are:

- EVEROLIMUS TABLET (AFINITOR) (ORAL)
- INLYTA (ORAL)
- LENVIMA (ORAL)
- PAZOPANIB TABLET (VOTRIENT) (ORAL)
- SUNITINIB (ORAL)

There were no further discussions made by the committee about this class.

Oncology, Oral-Skin

Recommendations for the PDL are:

- ERIVEDGE (ORAL)
- MEKINIST (ORAL)
- TAFINLAR (ORAL)

There were no further discussions made by the committee about this class.

Ophthalmic Antibiotics

Recommendations for the PDL are:

- BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)
- CIPROFLOXACIN SOLUTION (OPHTHALMIC)
- ERYTHROMYCIN (OPHTHALMIC)
- GENTAMICIN DROPS (OPHTHALMIC)
- MOXIFLOXACIN (AG) (VIGAMOX) (OPHTHALMIC)
- MOXIFLOXACIN (VIGAMOX) (OPHTHALMIC)
- OFLOXACIN (OPHTHALMIC)
- POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)
- SULFACETAMIDE SOLUTION (OPHTHALMIC)
- TOBRAMYCIN DROPS (OPHTHALMIC)

There were no further discussions made by the committee about this class.

Ophthalmic Antibiotic-Steroid Combinations

Recommendations for the PDL:

- NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)
- SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)
- TOBRADEX OINTMENT (OPHTHALMIC)
- TOBRAMYCIN / DEXAMETHASONE SUSPENSION (AG) (OPHTHALMIC)
- TOBRAMYCIN / DEXAMETHASONE SUSPENSION (OPHTHALMIC)

There were no further discussions made by the committee about this class.

Ophthalmics for Allergic Conjunctivitis

Recommendations for the PDL are:

- AZELASTINE (OPHTHALMIC)
- CROMOLYN SODIUM (OPHTHALMIC)
- OLOPATADINE (PATANOL) (OPHTHALMIC)

There were no further discussions made by the committee about this class.

Ophthalmics, Anti-Inflammatories

Recommendations for the PDL are:

- DEXAMETHASONE (OPHTHALMIC)
- DICLOFENAC (OPHTHALMIC)
- FLUOROMETHOLONE (OPHTHALMIC)
- FLURBIPROFEN (OPHTHALMIC)
- KETOROLAC (OPHTHALMIC)
- KETOROLAC LS (OPHTHALMIC)
- PREDNISOLONE ACETATE (OPHTHALMIC)

There were no further discussions made by the committee about this class.

Ophthalmics, Cystinosis

Recommendations for the PDL are:

- CYSTADROPS (OPHTHALMIC)
- CYSTARAN (OPHTHALMIC)

There were no further discussions made by the committee about this class.

Ophthalmics, Dry Eye Agents

Recommendations for the PDL are:

- CYCLOSPORINE (AG) (OPHTHALMIC)
- CYCLOSPORINE (OPHTHALMIC)
- XIIDRA (OPHTHALMIC)

There were no further discussions made by the committee about this class.

Ophthalmics, Glaucoma Agents

Recommendations for the PDL are:

- BRIMONIDINE 0.2% (OPHTHALMIC)
- BRIMONIDINE TARTRATE/TIMOLOL DROPS (AG) (OPHTHALMIC)
- BRIMONIDINE TARTRATE/TIMOLOL DROPS (OPHTHALMIC)
- CARTEOLOL (OPHTHALMIC)
- DORZOLAMIDE (OPHTHALMIC)
- DORZOLAMIDE / TIMOLOL (OPHTHALMIC)
- LATANOPROST 2.5 ML (OPHTHALMIC)
- LEVOBUNOLOL (OPHTHALMIC)
- RHOPRESSA (OPHTHALMIC)
- ROCKLATAN (OPHTHALMIC)
- SIMBRINZA (OPHTHALMIC)
- TIMOLOL (OPHTHALMIC)
- TRAVOPROST 2.5 ML (AG) (OPHTHALMIC)
- TRAVOPROST 2.5 ML (OPHTHALMIC)

- TRAVOPROST 5 ML (AG) (OPHTHALMIC)
- TRAVOPROST 5 ML (OPHTHALMIC)

There were no further discussions made by the committee about this class.

Otic Antibiotics

Recommendations for the PDL are:

- CIPROFLOXACIN/DEXAMETHASONE (AG) (OTIC)
- CIPROFLOXACIN/DEXAMETHASONE (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (AG) (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)
- OFLOXACIN (OTIC)

There were no further discussions made by the committee about this class.

Otic Anti-Infectives & Anesthetics

Recommendations for the PDL are:

- ACETIC ACID (OTIC)
- ACETIC ACID HC (OTIC)

There were no further discussions made by the committee about this class.

Progestational Agents

Recommendations for the PDL are:

- MEDROXYPROGESTERONE ACETATE (AG) (ORAL)
- MEDROXYPROGESTERONE ACETATE (ORAL)
- NORETHINDRONE ACETATE (ORAL)
- PROGESTERONE CAPSULE (ORAL)

There were no further discussions made by the committee about this class.

Sedative Hypnotics

Recommendations for the PDL are:

- ESZOPICLONE (ORAL)
- TEMAZEPAM (AG) (ORAL)
- TEMAZEPAM (ORAL)
- TRIAZOLAM (ORAL)
- ZOLPIDEM (ORAL)
- ZOLPIDEM ER (ORAL)

There were no further discussions made by the committee about this class.

Sickle Cell Anemia Treatments

Recommendations for the PDL are:

- DROXIA (ORAL)
- SIKLOS (ORAL)

There were no further discussions made by the committee about this class.

Smoking Cessation

Recommendations for the PDL are:

- BUPROPION SR (ORAL)
- NICOTINE GUM OTC (BUCCAL)
- NICOTINE LOZENGE OTC (BUCCAL)
- NICOTINE PATCH OTC (TRANSDERMAL)
- VARENICLINE DOSE PACK (ORAL)
- VARENICLINE TARTRATE (ORAL)

There were no further discussions made by the committee about this class.

Spinal Muscular Atrophy

Recommendations for the PDL are:

- ZOLGENSMA (INTRAVENOUS)

There were no further discussions made by the committee about this class.

Steroids, Topical High

Recommendations for the PDL are:

- BETAMET DIPROP / PROP GLY CREAM (TOPICAL)
- BETAMETHASONE VALERATE CREAM (TOPICAL)
- BETAMETHASONE VALERATE LOTION (TOPICAL)
- BETAMETHASONE VALERATE OINTMENT (TOPICAL)
- TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)
- TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)
- TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Steroids, Topical Low

Recommendations for the PDL are:

- HYDROCORTISONE CREAM (RECTAL)
- HYDROCORTISONE CREAM (TOPICAL)
- HYDROCORTISONE LOTION (TOPICAL)
- HYDROCORTISONE OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Steroids, Topical Medium

Recommendations for the PDL are:

- FLUTICASONE PROPIONATE CREAM (TOPICAL)
- FLUTICASONE PROPIONATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE CREAM (TOPICAL)
- MOMETASONE FUROATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE SOLUTION (TOPICAL)

There were no further discussions made by the committee about this class.

Steroids, Topical Very High

Recommendations for the PDL are:

- CLOBETASOL EMOLLIENT (TOPICAL)
- CLOBETASOL PROPIONATE CREAM (TOPICAL)
- CLOBETASOL PROPIONATE GEL (TOPICAL)
- CLOBETASOL PROPIONATE OINTMENT (TOPICAL)
- CLOBETASOL PROPIONATE SOLUTION (TOPICAL)
- HALOBETASOL PROPIONATE CREAM (TOPICAL)
- HALOBETASOL PROPIONATE OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Stimulants and Related Agents

Recommendations for the PDL are:

- AMPHETAMINE SALT COMBO (ORAL)
- AMPHETAMINE SALT COMBO ER (AG) (ORAL)
- AMPHETAMINE SALT COMBO ER (ORAL)
- ATOMOXETINE (ORAL)
- DEXMETHYLPHENIDATE (ORAL)
- DEXMETHYLPHENIDATE ER (ORAL)
- DEXTROAMPHETAMINE TABLET (ORAL)
- GUANFACINE ER (ORAL)
- LISDEXAMFETAMINE CAPSULE (ORAL)
- LISDEXAMFETAMINE CHEWABLE TABLET (ORAL)
- METHYLPHENIDATE (ORAL)
- METHYLPHENIDATE CD (AG) (ORAL)
- METHYLPHENIDATE CD (ORAL)
- METHYLPHENIDATE ER (CONCERTA) (ORAL)
- METHYLPHENIDATE ER (RITALIN LA) (ORAL)
- METHYLPHENIDATE SOLUTION (ORAL)

- MODAFINIL (ORAL)
- VYVANSE CAPSULE (ORAL)

There were no further discussions made by the committee about this class.

Thrombopoiesis Stimulating Proteins

Recommendations for the PDL are:

- ELTROMBOPAG SUSPENSION (PROMACTA) (ORAL)
- ELTROMBOPAG TABLET (PROMACTA) (ORAL)

There were no further discussions made by the committee about this class.

Urea Cycle Disorders

Recommendations for the PDL are:

- PHEBURANE (ORAL)
- SODIUM PHENYL BUTYRATE POWDER (ORAL)
- SODIUM PHENYL BUTYRATE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Single Drug Reviews

In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.

Presenter	Representing	Drug/Issue
Jay Mehta	Axsome Therapeutics	Symbravo
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

The single drugs were reviewed, and their recommendations are:

Angiotensin Modulators

Recommendations for the PDL are:

- ENTRESTO (ORAL) – recommended NPD
- SACUBITRIL / VALSARTAN TABLET (ORAL)- recommended preferred

Antimigraine Agents, Triptans

Recommendations for the PDL are:

- SYMBRAVO TABLET (ORAL)- recommended NPD

Beta-Blockers

Recommendations for the PDL are:

- LOPRESSOR SOLUTION (ORAL)- recommended NPD

Bone Resorption and Related Agents

Recommendations for the PDL are:

- JUBBONTI SYRINGE (SUBCUTANEOUS)- recommended preferred

BPH Treatments

Recommendations for the PDL are:

TEZRULY SOLUTION (ORAL)- recommended NPD

Growth Factors

Recommendations for the PDL are:

- EGRIFTA WR KIT (SUB-Q)- recommended NPD

HAE Treatments

Recommendations for the PDL are:

- DAWNZERA AUTOINJECTOR (SUB-Q)- recommended NPD
- EKTERLY (ORAL)- recommended NPD

HIV/AIDS

Recommendations for the PDL are:

- EDURANT PED TAB SUSP (ORAL)- recommended preferred
- YEZTUGO TABLET (ORAL) – recommended preferred
- YEZTUGO VIAL (SUBCUTANEOUS) – recommended preferred

Hypoglycemics, Insulin and Related Agents

Recommendations for the PDL are:

- KIRSTY PEN (SUBCUTANE.) – recommended NPD
- KIRSTY VIAL (SUBCUTANE.) – recommended NPD

New Antibiotics, Oral Uncomplicated UTI

Recommendations for the PDL are:

- ORLYNVAH TABLET (ORAL) – recommended NPD

Platelet Aggregation Inhibitors

Recommendations for the PDL are:

- BRILINTA (ORAL) – recommended NPD
- TICAGRELOR (ORAL) – recommended preferred

Proposed Therapeutic Classes to be Reviewed at Next Meeting

The committee members were shown the list of therapeutic classes that will be reviewed on the Spring 2026 meeting.

Next Meeting Date

The proposed date for the next P&T committee meeting is 5/6/2026 or 5/8/2026.

Adjournment

The meeting adjourned at or about 11:21 am CT.

 Ph.D., BCOP